

---

**SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**SCHEDULE 13D**

Under the Securities Exchange Act of 1934

**(Amendment No. 5)\***

**Day One Biopharmaceuticals, Inc.**

---

**(Name of Issuer)**

**Common Stock, par value \$0.0001 per share**

---

**(Title of Class of Securities)**

---

**(CUSIP Number)**

**Alejandro Moreno**  
**c/o Access Industries, Inc., 40 West 57th Street, 28th Floor**  
**New York, NY, 10019**  
**(212) 247-6400**

**Langhorne S. Perrow**  
**c/o Access Industries, Inc., 40 West 57th Street, 28th Floor**  
**New York, NY, 10019**  
**(212) 247-6400**

**Nicholas P. Pellicani**  
**Debevoise & Plimpton LLP, The Northcliffe, 28 Tudor St.**  
**London, X0, EC4Y 0AY**  
**44 20 7786 9000**

---

**(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)**

**04/09/2026**

---

**(Date of Event Which Requires Filing of This Statement)**

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

---

---

SCHEDULE 13D

CUSIP No.

1 Name of reporting person

AI Day1 LLC

Check the appropriate box if a member of a Group (See Instructions)

2  (a)

(b)

3 SEC use only

Source of funds (See Instructions)

4 AF

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5

Citizenship or place of organization

6 DELAWARE

Sole Voting Power

7 12,929,322.00

Number of Shares Beneficially

Shared Voting Power

Owned by Each Reporting Person

8 0.00

Sole Dispositive Power

9 12,929,322.00

Shared Dispositive Power

10 0.00

Aggregate amount beneficially owned by each reporting person

11 12,929,322.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

12   
Percent of class represented by amount in Row (11)

13 12.52 %

Type of Reporting Person (See Instructions)

14 OO

**Comment for Type of Reporting Person:** (1) All percentages of ownership of Common Stock by the Reporting Persons presented in this Statement are based on 103,297,691 shares of Common Stock outstanding as of February 19, 2026, as reported in the Issuer's Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (the "SEC") on February 24, 2026.

SCHEDULE 13D

CUSIP No.

1 Name of reporting person

Access Industries Holdings LLC

2 Check the appropriate box if a member of a Group (See Instructions)

(a)

(b)

3 SEC use only  
Source of funds (See Instructions)

4 AF  
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5   
Citizenship or place of organization

6 DELAWARE  
Sole Voting Power

7 0.00  
Number of Shares Beneficially Owned by Each Reporting Person With:

8 12,929,322.00  
Shared Voting Power  
Sole Dispositive Power

9 0.00  
Shared Dispositive Power

10 12,929,322.00  
Aggregate amount beneficially owned by each reporting person

11 12,929,322.00  
Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

12   
Percent of class represented by amount in Row (11)

13 12.52 %  
Type of Reporting Person (See Instructions)

14 OO

**Comment for Type of Reporting Person:** (1) All percentages of ownership of Common Stock by the Reporting Persons presented in this Statement are based on 103,297,691 shares of Common Stock outstanding as of February 19, 2026, as reported in the Issuer's Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on February 24, 2026.

## SCHEDULE 13D

### CUSIP No.

1 Name of reporting person  
Access Industries Management, LLC  
Check the appropriate box if a member of a Group (See Instructions)

2  (a)  
 (b)

3 SEC use only  
Source of funds (See Instructions)

4 AF  
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

Citizenship or place of organization  
6 DELAWARE  
Sole Voting Power  
7  
Number of Shares Beneficially Owned by Each Reporting Person With: 0.00  
Shared Voting Power  
8  
12,929,322.00  
Sole Dispositive Power  
9  
0.00  
Shared Dispositive Power  
10  
12,929,322.00  
Aggregate amount beneficially owned by each reporting person  
11  
12,929,322.00  
Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)  
12  
  
Percent of class represented by amount in Row (11)  
13  
12.52 %  
Type of Reporting Person (See Instructions)  
14  
OO  
**Comment for Type of Reporting Person:** (1) All percentages of ownership of Common Stock by the Reporting Persons presented in this Statement are based on 103,297,691 shares of Common Stock outstanding as of February 19, 2026, as reported in the Issuer's Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on February 24, 2026.

## SCHEDULE 13D

### CUSIP No.

1 Name of reporting person  
Len Blavatnik  
Check the appropriate box if a member of a Group (See Instructions)  
2  
 (a)  
 (b)  
3 SEC use only  
Source of funds (See Instructions)  
4  
AF  
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)  
5  
  
Citizenship or place of organization  
6  
UNITED STATES  
Number of Shares Beneficially Owned by Each Reporting Person With: 0.00  
7  
Shared Voting Power  
8

Person 12,929,322.00  
With: Sole Dispositive Power  
9  
0.00  
Shared Dispositive Power  
10  
12,929,322.00

Aggregate amount beneficially owned by each reporting person

11  
12,929,322.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

12

Percent of class represented by amount in Row (11)

13  
12.52 %

Type of Reporting Person (See Instructions)

14  
IN

**Comment for Type of Reporting Person:** (1) All percentages of ownership of Common Stock by the Reporting Persons presented in this Statement are based on 103,297,691 shares of Common Stock outstanding as of February 19, 2026, as reported in the Issuer's Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on February 24, 2026.

## SCHEDULE 13D

Item 1. Security and Issuer

Title of Class of Securities:

(a)  
Common Stock, par value \$0.0001 per share

Name of Issuer:

(b)  
Day One Biopharmaceuticals, Inc.

Address of Issuer's Principal Executive Offices:

(c)  
1800 Sierra Point Parkway, Suite 200, Brisbane, CALIFORNIA , 94005.

**Item 1 Comment:** This Amendment No. 5 to Schedule 13D is being filed by AI Day1 LLC ("AI Day1"), Access Industries Holdings LLC ("AIH"), Access Industries Management, LLC ("AIM") and Len Blavatnik (collectively, the "Reporting Persons", and each, a "Reporting Person"), in respect of the common stock, par value \$0.0001 per share (the "Common Stock"), of Day One Biopharmaceuticals, Inc. (the "Issuer"). The Schedule 13D filed with the Securities and Exchange Commission ("SEC") on June 9, 2021, as amended and supplemented by Amendment No. 1 to the Schedule 13D filed by the Reporting Persons with the SEC on June 21, 2022, Amendment No. 2 to the Schedule 13D filed by the Reporting Persons with the SEC on June 12, 2023, Amendment No. 3 to the Schedule 13D filed by the Reporting Persons with the SEC on October 20, 2023 and Amendment No. 4 to the Schedule 13D filed by the Reporting Persons with the SEC on August 1, 2024 (together, the "Schedule") is hereby amended and supplemented by the Reporting Persons as set forth below in this Amendment No. 5. This amendment is filed by the Reporting Persons in accordance with Rule 13d-2 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and refers only to information that has materially changed since the filing of the Schedule. The items identified below, or the particular paragraphs of such items which are identified below, are amended as set forth below. Unless otherwise indicated, all capitalized terms used and not defined herein have the respective meanings assigned to them in the Schedule.

Item 4. Purpose of Transaction

The disclosure in Item 4 is hereby supplemented by adding the following at the end thereof: On April 9, 2026, AI Day1 tendered all of its shares of Common Stock pursuant to the tender offer by Servier Detroit Inc. to purchase all of the issued and outstanding shares of Common Stock for \$21.50 per share in cash, upon the terms and subject to the conditions described in the Offer to Purchase and related Letter of Transmittal filed with the SEC on Schedule TO on March 26, 2026.

Item 5. Interest in Securities of the Issuer

(a) Item 5 of the Schedule 13D is hereby amended and restated as follows: The responses of each of the Reporting Persons with respect to Rows 11, 12, and 13 of the cover pages of this Schedule 13D that relate to the aggregate number and percentage of Common Stock (including but not limited to footnotes to such information) are

incorporated herein by reference. The responses of each of the Reporting Persons with respect to Rows 7, 8, 9, and 10 of the cover pages of this Schedule 13D that relate to the number of Common Stock as to which each of the persons or entities referenced in Item 2 above has sole or shared power to vote or to direct the vote of and sole or shared power to dispose of or to direct the disposition of (including but not limited to footnotes to such information) are incorporated herein by reference.

- (b) 12,929,322 shares of Common Stock and Warrants to purchase 827,586 shares of Common Stock are owned directly by AI Day1 and may be deemed to be beneficially owned by AIH, AIM and Mr. Blavatnik because (i) AIH indirectly controls all of the outstanding voting interests in AI Day1, (ii) AIM controls AIH and (iii) Mr. Blavatnik controls AIM and controls a majority of the outstanding voting interests in AIH. Each of the Reporting Persons (other than AI Day1), and each of their affiliated entities and the officers, partners, members and managers thereof, disclaims beneficial ownership of these securities.
- (c) The following transactions in the Issuer's securities have been effected by Reporting Persons within the 60 days prior to this filing: The information set forth in Item 3 of this Schedule 13D is incorporated by reference herein.
- (d) Not applicable.
- (e) Not applicable.

#### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

AI Day1 LLC

Signature: /s/ Alejandro Moreno  
By: Access Industries Management, LLC, its  
Name/Title: Manager; its Executive Vice President/Alejandro Moreno  
Date: 04/13/2026

Access Industries Holdings LLC

Signature: /s/ Alejandro Moreno  
By: Access Industries Management, LLC, its  
Name/Title: Manager; its Executive Vice President/Alejandro Moreno  
Date: 04/13/2026

Access Industries Management, LLC

Signature: /s/ Alejandro Moreno  
Name/Title: By: Executive Vice President/Alejandro Moreno  
Date: 04/13/2026

Len Blavatnik

Signature: \*  
Name/Title: Len Blavatnik  
Date: 04/13/2026

**Comments accompanying signature:** \* The undersigned, by signing his name hereto, executes this Amendment No. 5 to Schedule 13D pursuant to the Limited Power of Attorney executed on behalf of Mr. Blavatnik and filed herewith. By: /s/ Alejandro Moreno Name: Alejandro Moreno Attorney-in-Fact